As tension mounts over drug-pricing policy, pharmaceutical company Abbott says it will not be launching seven new drugs in Thailand, including treatments for HIV and bacterial infections. The move follows the country's decision to issue 'compulsory licences' that allow it to make or import cheap versions of several patented drugs. One of these is Kaletra, an anti-HIV drug from Abbott. The company says it decided to withhold the new drugs on the grounds that it can no longer defend its patents in Thailand.
展开▼
